Rivian Faces Biggest Short-Term Threat: What Investors Need to Know
Rivian has captured imaginations—and capital. But the next 12 months will test its ability to scale, control costs, a...
Essential financial guidance tailored for young adults to establish solid budgeting and saving foundations from the start.
15,700 articlesRivian has captured imaginations—and capital. But the next 12 months will test its ability to scale, control costs, a...
Fridays bring a fresh round of analyst calls that moved key names across tech and consumer staples. Investors weigh n...
Investors are asking what the next five years hold for XRP. This guide breaks down plausible paths, key catalysts, ri...
As investors scan the horizon for regenerative medicine players, Avita (RCEL) faces a pivotal quarter. This guide bre...
A niche nuclear tech stock reported solid revenue gains, but a large fund reduced its holdings. Learn how to read the...
SpaceX is charging toward a historic IPO, aiming for a mid-June pricing and a Nasdaq debut under SPCX. The deal could...
Investing in critical metals blends opportunity with policy risk. This guide breaks down how to evaluate this critica...
Citigroup has quietly strengthened its fundamentals while stock performance has turned a corner. This guide breaks do...
A cross-chain breach targeting the Verus-Ethereum bridge drained more than $11 million, triggering renewed focus on s...
Investors often wrestle with where to place bets: a volatile crypto project or a disruptive nuclear-tech equity. This...
Local towns are pushing back on megascale data centers even as tech giants accelerate capex toward a multi-trillion-d...
A major hedge fund just disclosed a multi-million stake in Crinetics, a rare-disease biotech. This article unpacks wh...